α-naphthyl(tert-butyloxy-L-alaninyl) phosphorochloridate | 874362-30-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: α-naphthyl(tert-butyloxy-L-alaninyl) phosphorochloridate
• 英文别名: 1-naphthyl-(tert-butoxy-L-alaninyl)-phosphorochloridate；1-naphthyl-(tert-butoxy-L-alaninyl)phosphochloridate；α-naphthyl(tert-butoxy-L-alaninyl)phosphorochloridate；tert-butyl (2S)-2-[[chloro(naphthalen-1-yloxy)phosphoryl]amino]propanoate
• CAS: 874362-30-8
• 化学式: C₁₇H₂₁ClNO₄P
• 分子量: 369.785
• InChiKey: VBOAJPDXCPXBRV-JMSDCMLSSA-N

物化性质

• 沸点：
  468.8±47.0 °C(Predicted)
• 密度：
  1.254±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  α-naphthyl(tert-butyloxy-L-alaninyl) phosphorochloridate 、 溴夫定 在 N-甲基咪唑 作用下， 以 四氢呋喃 为溶剂， 反应 12.0h， 以25%的产率得到(E)-5-(2-bromovinyl)-2'-deoxyuridine-5'-[1-naphthyl-(tert-butoxy-L-alaninyl)]phosphate
  参考文献：
  名称：

  Novel Potential Anticancer Naphthyl Phosphoramidates of BVdU:  Separation of Diastereoisomers and Assignment of the Absolute Configuration of the Phosphorus Center

  摘要：

  We have previously reported our SAR optimization of the anticancer agent thymectacin. Tuning of the parent ProTide structure initially involved the amino acid and, subsequently, the aromatic masking group on the phosphate moiety. Herein, derivatives bearing the combined modifications are reported and biological evaluation is described. Moreover, separation of the diastereoisomeric final product mixture shows a different cytostatic activity for the two diastereoisomers. Through computational and NMR studies, the absolute stereochemistry of the phosphorus center of the two diastereoisomers has been suggested.

  DOI：

  10.1021/jm0509896
• 作为产物：
  描述：

  L-丙氨酸叔丁酯 、 1-萘基二氯磷酸酯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 α-naphthyl(tert-butyloxy-L-alaninyl) phosphorochloridate
  参考文献：
  名称：

  Novel Potential Anticancer Naphthyl Phosphoramidates of BVdU:  Separation of Diastereoisomers and Assignment of the Absolute Configuration of the Phosphorus Center

  摘要：

  We have previously reported our SAR optimization of the anticancer agent thymectacin. Tuning of the parent ProTide structure initially involved the amino acid and, subsequently, the aromatic masking group on the phosphate moiety. Herein, derivatives bearing the combined modifications are reported and biological evaluation is described. Moreover, separation of the diastereoisomeric final product mixture shows a different cytostatic activity for the two diastereoisomers. Through computational and NMR studies, the absolute stereochemistry of the phosphorus center of the two diastereoisomers has been suggested.

  DOI：

  10.1021/jm0509896

文献信息

• The phosphoramidate ProTide approach greatly enhances the activity of β-2′-C-methylguanosine against hepatitis C virus
  作者：Christopher McGuigan、Plinio Perrone、Karolina Madela、Johan Neyts

  DOI：10.1016/j.bmcl.2009.05.122

  日期：2009.8

  l-alanine phosphoramidate derivatives with variations to the amino acid ester. The 1-naphthyl phosphoramidate of β-2′-methylguanosine containing the benzyl ester (20) was the most active at 0.12 μM, an 84-fold of increase in activity compared to the parent nucleoside (2) with no increase of cytotoxicity. The carboxypeptidase mediated hydrolysis of several ProTides showed a predictive correlation with their

  β-2'-C-甲基嘌呤（1，2）是已知的丙型肝炎病毒（HCV）的抑制剂。我们在此报告了其5'-磷酸氨基甲酸酯ProTides的合成，生物学和酶学评估。本文描述了七个具有氨基酸酯变化的1-丙氨酸氨基磷酸酯衍生物。含苄基酯（20）的β-2'-甲基鸟苷的1-萘基氨基磷酸酯活性最高，为0.12μM，与亲本核苷（2）相比，活性增加了84倍，而细胞毒性没有增加。羧肽酶介导的几种ProTide的水解显示其与复制子中HCV的活性之间的预测相关性。
• First Example of Phosphoramidate Approach Applied to a 4‘-Substituted Purine Nucleoside (4‘-Azidoadenosine):  Conversion of an Inactive Nucleoside to a Submicromolar Compound versus Hepatitis C Virus
  作者：Plinio Perrone、Felice Daverio、Rocco Valente、Sonal Rajyaguru、Joseph A. Martin、Vincent Lévêque、Sophie Le Pogam、Isabel Najera、Klaus Klumpp、David B. Smith、Christopher McGuigan

  DOI：10.1021/jm070362i

  日期：2007.11.1

  We report on the synthesis of the anti hepatitis C virus (HCV) agent 4'-azidoadenosine (1) and the application of the phosphoramidate ProTide technology to this nucleoside. The synthesis of 1 was achieved through an epoxide intermediate followed by regio- and stereoselective ring opening by azidotrimethylsilane in the presence of a Lewis acid. Compound 1 did not inhibit HCV replication in cell culture

  我们报告了抗丙型肝炎病毒（HCV）剂4'-叠氮腺苷（1）的合成，以及氨基磷酸酯ProTide技术在该核苷中的应用。1的合成是通过环氧化物中间体，然后在路易斯酸存在下通过叠氮基三甲基硅烷进行区域和立体选择性开环而实现的。化合物1在浓度高达0.1 mM的细胞培养物中不抑制HCV复制。但是，通过应用ProTide技术，亚微摩尔活性剂可衍生自1。所制备的所有氨基磷酸酯均为L-丙氨酸衍生物，其氨基酸的芳基部分和酯部分有所变化。在复制子测定中，苄基酯和1-萘基磷酸酯（18）具有最佳活性。
• Process for preparing nucleoside prodrugs
  申请人：University College Cardiff Consultants Limited

  公开号：US10005810B2

  公开（公告）日：2018-06-26

  Provided are phosphoramidate nucleoside compounds of Formula (I), or pharmaceutically acceptable salts or esters or solvates thereof, useful in the treatment of cancer, viral infections and other diseases: Also provided is a process for the synthesis of the compounds of Formula (I) where a desired enantiomer, having regard to the asymmetric chiral center of the phosphorus atom P, is provided in an enriched amount. The process comprises admixing a nucleoside with a phosphorochloridate in the presence of a catalyst comprising a metal salt selected from the group consisting of salts of Cu, Fe, La and Yb.

  本研究提供了可用于治疗癌症、病毒感染和其他疾病的式 (I) 磷酰胺核苷化合物或其药学上可接受的盐或酯或溶剂： 还提供了一种合成式（I）化合物的工艺，在该工艺中，根据磷原子 P 的不对称手性中心，可提供所需的对映体，且对映体的含量较高。该工艺包括在由选自铜、铁、喇和镱盐组成的金属盐催化剂存在下，将核苷与氯代磷酸盐混合。
• The application of the phosphoramidate ProTide approach confers micromolar potency against Hepatitis C virus on inactive agent 4′-azidoinosine: Kinase bypass on a dual base/sugar modified nucleoside
  作者：Christopher McGuigan、Felice Daverio、Isabel Nájera、Joseph A. Martin、Klaus Klumpp、David B. Smith

  DOI：10.1016/j.bmcl.2009.03.138

  日期：2009.6

  Novel phosphoramidate ProTides derived from 4'-azidoinosine have been prepared and evaluated in the replicon assay against hepatitis C Virus (HCV). The parent nucleoside analogue is inactive in this assay, while the ProTides are active at low mu M levels in some cases. This is a rare example of an inosine nucleoside analogue with potent antiviral activity and further supports the notion of ProTides as a drug discovery motif. (C) 2009 Elsevier Ltd. All rights reserved.
• The Application of Phosphoramidate Protide Technology to Acyclovir Confers Anti-HIV Inhibition
  作者：Marco Derudas、Davide Carta、Andrea Brancale、Christophe Vanpouille、Andrea Lisco、Leonid Margolis、Jan Balzarini、Christopher McGuigan

  DOI：10.1021/jm9007856

  日期：2009.9.10

  Recently, it has been reported that phosphorylated acyclovir (ACV) inhibits human immunodeficiency virus type 1 (HIV-1) reverse transcriptase in a cell-free system. To deliver phosphorylated ACV inside cells, we designed ACV monophosphorylated derivatives using ProTide technology. We found that the L-alanine derived ProTides show anti-HIV activity at noncytotoxic concentrations; ester and aryl variation was tolerated, ACV ProTides with other amino acids, other than L-phenylalanine, showed no detectable activity against HIV in cell culture. The inhibitory activity of the prodrugs against herpes simplex virus (HSV) types-1 and -2 and thymidine kinase-deficient HSV-1 revealed different structure-activity relationships but was again consistent with successful nucleoside kinase bypass. Enzymatic and molecular modeling studies have been performed in order to better understand the antiviral behavior of these compounds. ProTides showing diminished carboxypeptidase lability translated to poor anti-HIV agents and vice versa, so the assay became predictive.